Internal Medicine, Hematology & Oncology · Los Angeles, CA
NPI
1992725865
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
11800 Wilshire Blvd Fl 3
Los Angeles, CA, 90025
Phone (310) 582-7900
Groups this clinician bills Medicare through
Medicare paid, 2024
$958K
53,402 services
Medicare patients, 2024
140
Average age 75
Drug cost, 2024
$613K
234 prescriptions
Company payments, 2025
$31.05
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Vi K Chiu was code J9263 (injection, oxaliplatin, 0.5 mg), 15,732 times for 15 patients. In total Vi K Chiu billed 53,402 services in 114 codes, and Medicare paid $958K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-06-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 15,732 | 15 | $0.05 | $832 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,010 | 21 | $0.09 | $87.71 |
| J1626 Injection, granisetron hydrochloride, 100 mcg | Office | 890 | 18 | $0.25 | $225 |
| 85025 Blood Count | Office | 314 | 62 | $7.61 | $2,390 |
| 80053 Clinical Chemistry | Office | 308 | 62 | $10.35 | $3,188 |
| 99215 Office E&M - Established | Office | 249 | 68 | $147.89 | $37K |
| 96413 Chemotherapy Administration | Office | 187 | 27 | $117.59 | $22K |
| 99232 Hospital E&M - Subsequent | Facility | 175 | 49 | $64.57 | $11K |
| 96375 Injection Administration | Office | 149 | 18 | $13.90 | $2,071 |
| 82378 Clinical Chemistry | Office | 119 | 28 | $18.58 | $2,211 |
| 96367 Intravenous Infusion, Hydration | Office | 104 | 17 | $25.76 | $2,679 |
| 96415 Chemotherapy Administration | Office | 103 | 14 | $24.51 | $2,524 |
| 83615 Clinical Chemistry | Office | 91 | 39 | $5.92 | $539 |
| 96372 Injection Administration | Office | 91 | 25 | $12.42 | $1,130 |
| 82977 Clinical Chemistry | Office | 88 | 36 | $7.06 | $621 |
By year: 2022 $869K for 65,652 services; 2023 $978K for 87,025 services; 2024 $958K for 53,402 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 314 | 62 | $7.61 | $2,390 |
| 80053 Clinical Chemistry | 308 | 62 | $10.35 | $3,188 |
| 82378 Clinical Chemistry | 119 | 28 | $18.58 | $2,211 |
| 83615 Clinical Chemistry | 91 | 39 | $5.92 | $539 |
| 82977 Clinical Chemistry | 88 | 36 | $7.06 | $621 |
| 84100 Clinical Chemistry | 82 | 37 | $4.65 | $381 |
| 84550 Clinical Chemistry | 81 | 38 | $4.43 | $359 |
| 36415 Venipuncture Blood Collection | 80 | 40 | $8.65 | $692 |
| 86140 Clinical Chemistry | 72 | 11 | $5.08 | $366 |
| 86301 Immunoassay | 61 | 11 | $20.39 | $1,244 |
Medicare prescription drug claims, 2024
In 2024, the drug Vi K Chiu prescribed most often to Medicare patients was Oxycodone Hcl, with 21 prescriptions and refills. In total Vi K Chiu wrote 234 Medicare prescriptions that cost $613K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Oxycodone Hcl Generic | 21 | 21 | Under 11 | $417 |
| Stivarga Regorafenib | 20 | 26 | Under 11 | $454K |
| Diphenoxylate-Atropine Diphenoxylate Hcl/Atropine | 18 | 18 | Under 11 | $379 |
| Ondansetron Odt Ondansetron | 14 | 14 | Under 11 | $295 |
| Ondansetron Hcl Generic | 14 | 14 | Under 11 | $116 |
Brand drugs: - claims; generic drugs: 156 claims; opioid claims: 29.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Vi K Chiu $31.05 ($31.05 in general payments such as food, travel and fees) from 3 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $31.05.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 1 | $31.05 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.